The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Youfuding     5-fluoro-1-(oxolan-2- yl)pyrimidine-2,4...

Synonyms: Ufur, Tegafur-Uracil, Uracil-Tegafur, SureCN8228, Uftoral (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Uftoral


High impact information on Uftoral


Chemical compound and disease context of Uftoral


Biological context of Uftoral


Anatomical context of Uftoral


Associations of Uftoral with other chemical compounds


Gene context of Uftoral


Analytical, diagnostic and therapeutic context of Uftoral


  1. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. Hamada, C., Tanaka, F., Ohta, M., Fujimura, S., Kodama, K., Imaizumi, M., Wada, H. J. Clin. Oncol. (2005) [Pubmed]
  2. Suppression of mediastinal metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II) using a lymphogenous metastatic model in a human lung cancer cell line. Ishikura, H., Kondo, K., Miyoshi, T., Kinoshita, H., Takahashi, Y., Fujino, H., Monden, Y. Clin. Cancer Res. (2001) [Pubmed]
  3. Adjuvant chemotherapy with uracil-tegafur prolongs overall survival in people with primary adenocarcinoma of the lung. Evans, W.K. Cancer Treat. Rev. (2004) [Pubmed]
  4. Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Ueno, H., Okada, S., Okusaka, T., Ikeda, M., Kuriyama, H. Oncology (2002) [Pubmed]
  5. Evaluation of intensive adjuvant chemotherapy in gastric cancer using life expectancy compared with log-rank test as a measure of survival benefit. Nishikawa, T., Maetani, S. Ann. Surg. Oncol. (2007) [Pubmed]
  6. Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Feliu, J., Vicent, J.M., García-Girón, C., Constela, M., Fonseca, E., Aparicio, J., Lomas, M., Antón-Aparicio, L., Dorta, F.J., Gonzalez-Baron, M. Br. J. Cancer (2004) [Pubmed]
  7. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. Veronese, M.L., Stevenson, J.P., Sun, W., Redlinger, M., Algazy, K., Giantonio, B., Hahn, S., Vaughn, D., Thorn, C., Whitehead, A.S., Haller, D.G., O'Dwyer, P.J. Eur. J. Cancer (2004) [Pubmed]
  8. A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary results. Veerasarn, V., Lorvidhaya, V., Kamnerdsupaphon, P., Suntornpong, N., Sangruchi, S., Lertsanguansinchai, P., Khorprasert, C., Sookpreedee, L., Udompunturak, S. Gynecol. Oncol. (2007) [Pubmed]
  9. Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. Uzcudun, A.E., Batlle, J.F., Velasco, J.C., Sánchez Santos, M.E., Carpeño, J.d.e. .C., Grande, A.G., Juberías, A.M., Piñeiro, E.H., Olivar, L.M., García, A.G. Dis. Colon Rectum (2002) [Pubmed]
  10. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. Nio, Y., Hashimoto, K., Yano, S., Itakura, M., Koike, M., Yamaguchi, K., Endo, S., Tsuji, M., Higami, T., Maruyama, R. Oncol. Rep. (2005) [Pubmed]
  11. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Tsujie, M., Nakamori, S., Nakahira, S., Takeda, S., Takahashi, Y., Hayashi, N., Okami, J., Nagano, H., Dono, K., Umeshita, K., Sakon, M., Monden, M. Pancreas (2006) [Pubmed]
  12. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Akasu, T., Moriya, Y., Ohashi, Y., Yoshida, S., Shirao, K., Kodaira, S. Jpn. J. Clin. Oncol. (2006) [Pubmed]
  13. Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer? Tachikawa, D., Arima, S., Futami, K., Iwashita, A. Anticancer Res. (2000) [Pubmed]
  14. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Chen, J.S., Huang, J.S., Yang, T.S., Lin, Y.C., Wang, H.M., Liau, C.T., Rau, K.M. Anticancer Drugs (2005) [Pubmed]
  15. Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. Lin, J.K., Wang, W.S., Hsieh, R.K., Hsu, T.C., Chiou, T.J., Liu, J.H., Fan, F.S., Yen, C.C., Lin, T.C., Jiang, J.K., Yang, S.H., Wang, H.S., Chen, P.M. Jpn. J. Clin. Oncol. (2000) [Pubmed]
  16. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Ikeda, M., Okusaka, T., Ueno, H., Morizane, C., Furuse, J., Ishii, H. Jpn. J. Clin. Oncol. (2005) [Pubmed]
  17. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. Yamashita, K., Yada, H., Ariyoshi, T. The Journal of toxicological sciences. (2004) [Pubmed]
  18. Advanced adenocarcinoma of the urinary bladder successfully treated by the combination of cisplatinum, mitomycin-C, etoposide and tegafur-uracil chemotherapy. Kasahara, K., Inoue, K., Shuin, T. International journal of urology : official journal of the Japanese Urological Association. (2001) [Pubmed]
  19. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines. Ojima, E., Inoue, Y., Watanabe, H., Hiro, J., Toiyama, Y., Miki, C., Kusunoki, M. Oncol. Rep. (2006) [Pubmed]
  20. Early Phase II Study of Uracil-Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer. Furuse, J., Okusaka, T., Funakoshi, A., Yamao, K., Nagase, M., Ishii, H., Nakachi, K., Ueno, H., Ikeda, M., Morizane, C., Horikawa, Y., Mizuno, N. Jpn. J. Clin. Oncol. (2006) [Pubmed]
  21. Current stage-specific chemotherapeutic options in colon cancer. Martin, M.J. Expert review of anticancer therapy. (2005) [Pubmed]
  22. Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. Kawasaki, G., Yoshitomi, I., Yanamoto, S., Mizuno, A. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. (2002) [Pubmed]
  23. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Ichikura, T., Tomimatsu, S., Okusa, Y., Yahara, T., Uefuji, K., Tamakuma, S. Cancer Chemother. Pharmacol. (1996) [Pubmed]
  24. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Spindler, K.L., Nielsen, J.N., Lindebjerg, J., Brandslund, I., Jakobsen, A. Int. J. Radiat. Oncol. Biol. Phys. (2006) [Pubmed]
  25. AUC of Calvert's formula in targeted intra-arterial carboplatin chemoradiotherapy for cancer of the oral cavity. Oya, R., Nakamura, S., Ikemura, K., Takagi, S., Mugino, H. Br. J. Cancer (2004) [Pubmed]
  26. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Pazdur, R., Lassere, Y., Diaz-Canton, E., Bready, B., Ho, D.H. Anticancer Drugs (1996) [Pubmed]
WikiGenes - Universities